Experimental Alzheimer's Drug Shows Promise
More than five million Americans suffer from Alzheimer's disease, and as the Baby Boomer generation ages, the terrible toll of the disease is expected to keep growing. There hasn't been a new drug approved to treat Alzheimer's in a decade, but researchers are working hard to change that. A clinical trial is now underway to test a new drug that shows promise for slowing the relentless progression of memory loss and mental decline in Alzheimer's patients. The drug is called T-817MA and it's designed to protect nerve cells in the brain. "We are absolutely hoping it can prevent cognitive decline, it will prevent the disease from progressing and prevent the clinical changes that happen," said Dr. Amy Aloysi, a specialist in geriatric psychiatry at Mount Sinai Hospital in New York City, one of the hospitals taking part in the trial.
-Amy Aloysi, MD, Assistant Professor, Psychiatry, Neurology, Icahn School of Medicine at Mount Sinai